Physician profile
Scot E West
NPI 1851896013
$5,246.02
in general payments reported to CMS, 2019-2025
16 companies · $1,658 in 2025
The $1,658 reported for 2025 was more than what 89% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,054 · 2022: $924 · 2023: $870 · 2024: $739 · 2025: $1,658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,253 · Education: $15.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,252.75 |
| Education | $15.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,325.23 | 2021-2025 | |
| Alkermes, INC. | $890.30 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Lundbeck LLC | $826.46 | 2021-2025 | Rexulti, Abilify Maintena |
| Otsuka America Pharmaceutical, INC. | $560.53 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $559.47 | 2021-2025 | Spravato, Invega Sustenna |
| E.R. Squibb & Sons, L.L.C. | $351.75 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $200.36 | 2021-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $159.36 | 2021-2025 | Fanapt |
| Axsome Therapeutics, INC. | $104.41 | 2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $92.31 | 2021-2025 | Uzedy, Austedo Xr |
| Supernus Pharmaceuticals, INC. | $59.16 | 2023-2025 | Qelbree, Qelbree |
| Sunovion Pharmaceuticals INC. | $34.48 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.57 | 2022 | |
| Noven Therapeutics, LLC | $22.49 | 2021 | |
| Neos Therapeutics, LP | $17.34 | 2025 | Exxua |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $11.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scot West listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.